BCG041 / Biocytogen - LARVOL DELTA

BCG041: A first-in-class bispecific ADC targeting B7-H3 and the proximal membrane region of MUC1 with superior antitumor activity (AACR 2026) - "In vitro, BCG041 demonstrated stronger binding and faster internalization than naked DS-7300 or Gatipotuzumab analogs across multiple tumor cell lines. Pharmacokinetic evaluation revealed a favorable ADC profile, and this drug demonstrates excellent developability, with CMC cell-line development currently ongoing. Together, these data position BCG041 as a highly promising next-generation bispecific ADC for B7-H3/MUC1-positive malignancies, addressing significant unmet clinical needs in breast, lung, gastro-esophageal, head-and-neck, colorectal, prostate, and ovarian cancers."

ADC • Bispecific • Breast Cancer • Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • CD276 • MUC1